NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.088
+0.008 (0.74%)
Sep 2, 2026, 5:08 PM CET
NextCell Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Operating Revenue | 10.54 | 9.62 | 10.94 | 10.66 | 10.11 | 5.59 |
Other Revenue | 0.24 | 0.21 | 0.13 | 0.61 | 3.84 | 0.64 |
| 10.78 | 9.83 | 11.06 | 11.28 | 13.96 | 6.23 | |
Revenue Growth | 3.05% | -11.13% | -1.90% | -19.18% | 124.03% | 39.82% |
Cost of Revenue | 7.28 | 8.18 | 9.4 | 15.22 | 11 | 8.72 |
Gross Profit | 3.5 | 1.66 | 1.67 | -3.94 | 2.96 | -2.49 |
Selling, General & Admin | 43.6 | 38.66 | 34.9 | 38.22 | 43.47 | 31.85 |
Other Operating Expenses | -0.02 | -0.04 | 0.14 | 0.04 | 0.04 | 0.22 |
Operating Expenses | 46.07 | 41.11 | 37.55 | 39.23 | 43.96 | 32.53 |
Operating Income | -42.57 | -39.46 | -35.89 | -43.17 | -41 | -35.02 |
Interest Expense | -0 | -0 | -0 | -0 | -0 | -0.01 |
Interest & Investment Income | 0.47 | 0.67 | 0.75 | 1.21 | 1.19 | 0.48 |
Pretax Income | -42.11 | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 |
Net Income | -42.11 | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 |
Net Income to Common | -42.11 | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 126 | - | 76 | 41 | 34 | 34 |
Shares Outstanding (Diluted) | 126 | - | 76 | 41 | 34 | 34 |
Shares Change | 110.06% | - | 87.22% | 18.72% | - | 13.05% |
EPS (Basic) | -0.33 | - | -0.46 | -1.03 | -1.16 | -1.01 |
EPS (Diluted) | -0.33 | - | -0.46 | -1.03 | -1.16 | -1.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Free Cash Flow | -46.31 | -46.57 | -43.05 | -37.86 | -47.92 | -40.9 |
Free Cash Flow Per Share | -0.37 | - | -0.56 | -0.93 | -1.39 | -1.19 |
Gross Margin | 32.48% | 16.84% | 15.07% | -34.98% | 21.19% | -40.03% |
Operating Margin | -394.97% | -401.24% | -324.35% | -382.79% | -293.81% | -562.26% |
Profit Margin | -390.69% | -394.49% | -317.62% | -372.04% | -285.28% | -554.72% |
Free Cash Flow Margin | -429.66% | -473.62% | -389.04% | -335.70% | -343.41% | -656.63% |
EBITDA | -40.08 | -36.96 | -33.37 | -42.2 | -40.55 | -34.57 |
EBITDA Margin | - | - | - | - | -290.60% | - |
D&A For EBITDA | 2.5 | 2.49 | 2.52 | 0.97 | 0.45 | 0.46 |
EBIT | -42.57 | -39.46 | -35.89 | -43.17 | -41 | -35.02 |
EBIT Margin | - | - | - | - | -293.81% | - |
Revenue as Reported | 10.78 | 9.83 | 11.06 | 11.28 | 13.96 | 6.23 |